Evidence review · Searched 2026-07-31
Best peptides for women, judged on whether anyone has tested them in women
We ran 13 PubMed searches for this page and 7 of them returned nothing at all. Every query and every count is printed below, so you can check us. Of the 5 compound groups sold into this market, 4 have any human data in women and only 1 rests on a controlled trial of something you would notice. Meanwhile the two facts that genuinely change a woman's decision turn out not to be efficacy findings at all — they are two lines of FDA labelling, and they point in opposite directions.
The two things a label says about you that it does not say about a man
Tirzepatide and the pill: 4 weeks, twice over
Zepbound §7.2 and §8.3 advise anyone on an oral hormonal contraceptive to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. §12.3 measured why: mean peak ethinyl estradiol down 59%, norgestimate 66%, norelgestromin 55% alongside a single 5 mg dose. Mounjaro carries the same instruction. Semaglutide does not — and dedicated studies found no reduction in oral-contraceptive bioavailability with semaglutide or liraglutide, so that is an absence backed by measurement.
Semaglutide and a planned pregnancy: 2 months
Wegovy §8.3 in full: because of the potential for fetal harm, discontinue at least 2 months before a planned pregnancy, to account for the long half-life. Ozempic repeats it. Neither tirzepatide label states any pre-conception interval, so the rule does not transfer. Both drugs instruct stopping when a pregnancy is recognised, and both say weight loss offers no benefit in pregnancy and may cause fetal harm — those are hard exclusions, not footnotes.
Read together they are a real decision: on the pill, semaglutide is simpler; trying to conceive within the year, tirzepatide sets no waiting period. Which makes the molecule you are prescribed a thing worth controlling — we rank providers on exactly that. Every quote was read from the current prescribing information on DailyMed on 2026-07-31, and none of it carries over to a compounded product, which has no FDA label at all.
The claim we expected to find, and did not
We started this page expecting FDA labels to carry sex-split efficacy rows worth more than the headline number. They do not carry them at all. Wegovy §14.2 and Zepbound §14.1 both state only that weight reduction was seen irrespective of sex, and all four labels we read say sex has no clinically relevant effect on how the drug is handled. The widely repeated line that women respond dramatically better has no label basis.
It has some support in the literature, and it is smaller than the confidence around it: pooled across 14 studies, women lost about 1 kg and 1.7 percentage points more, with no difference at all for exenatide. A 2026 review found only about a fifth of trials analysed by sex in the first place, and no sex-subgroup analysis has been published for tirzepatide specifically. There is one mechanism that gets mistaken for this: semaglutide exposure falls as body weight rises, and women weigh less on average. That is a weight effect, and repeating it as a sex effect would be an inference the label explicitly declines to make.
The one genuine, quantified, sex-split row in either label is an adverse reaction. Wegovy §6.1 reports hair loss in 4% of women against 0.9% of men at 2.4 mg, and 8.4% against 0.2% at 7.2 mg; Zepbound §6.1 reports 7.1% against 0.5%. Both attribute it to the weight reduction rather than the drug, which fits the proposed mechanism of telogen effluvium after rapid loss and means it is generally reversible. Separately, the cardiovascular outcomes trial reported hip and pelvis fractures in 1% of women on Wegovy against 0.2% on placebo. Neither is a reason not to treat obesity. Both are things you are entitled to have been told.
Every compound, and the searches behind the verdict
Ordered by the strength of the human evidence in women, not by popularity. Nothing here is a product we can be paid for, so no row carries a commercial link — the only links out of a row go to our own evidence pages and to PubMed.
- Clinical outcomes
Semaglutide and tirzepatide
The two compounded GLP-1 molecules every provider on our boards sells.
The only compounds on this page with randomized human evidence on outcomes a person would notice — and the only ones whose labelling says anything sex-specific at all. Pooled across GLP-1 receptor agonists, women lose about 1 kg and 1.7 percentage points more than men: real, consistent in direction, and too small to change a recommendation. Only about a fifth of the trials analysed by sex at all.
2 searches run · 1 returned nothing
GLP-1 receptor agonist sex differences weight loss meta-analysis14 recordsFourteen studies pooled; the sex difference is about 1 kg, and no sex difference at all for exenatide.
tirzepatide sex subgroup weight loss0 recordsNo published sex-subgroup analysis for tirzepatide specifically. Anything claiming women lose more on tirzepatide is extrapolating from the wider drug class.
PubMed, run 2026-07-31. Paste any query above to check it yourself — these are the searches behind the claim that no evidence in women exists, and a claim like that is worth nothing if you cannot repeat it.
Sources: Yang Y 2025; Alexander GC 2026; Novo Nordisk 2026; Eli Lilly and Company 2026
- Surrogate endpoints
GLP-1s in PCOS specifically
The one indication where the trials were run in women by design.
Randomized trials in women with PCOS show weight and waist reduction, a lower free androgen index, higher SHBG, less liver and visceral fat, and modestly more regular bleeding. They do not show live birth, and the 2023 international guideline recommends anti-obesity agents in PCOS for reproductive outcomes only in research settings. Two meta-analyses disagree on whether insulin resistance improves at all.
2 searches run · 1 returned nothing
GLP-1 receptor agonist polycystic ovary syndrome randomized controlled trial11 recordsEleven trials, 545 treated. The guideline's own systematic review calls the published data "very limited" and could pool only two comparisons.
GLP1RA polycystic ovary syndrome live birth0 recordsNo trial has reported live birth as an outcome.
PubMed, run 2026-07-31. Paste any query above to check it yourself — these are the searches behind the claim that no evidence in women exists, and a claim like that is worth nothing if you cannot repeat it.
Sources: Teede HJ 2023; Goldberg A 2024; Nylander M 2017; Zhou L 2023; Elkind-Hirsch KE 2022
- Surrogate endpoints
Sermorelin and the GH-releasing peptides
The GHRH analogue behind almost every prescribed "GH peptide" programme.
No randomized trial is indexed under the name sermorelin. The relevant human data sits under GHRH(1-29): a 1997 single-blind study of ten women and nine men found overnight growth-hormone secretion rose 107% in the men and 70% in the women, with IGF-1 up 28% in both. That is a real sex-split — on a hormone level, in nineteen people, thirty years ago, with no body-composition or clinical endpoint anywhere in it.
3 searches run · 2 returned nothing
sermorelin[tiab] AND randomized controlled trial[pt]0 recordsNo randomized trial indexed under this name.
sermorelin[tiab] AND (women OR postmenopausal)[tiab]1 recordOne record — a 1990 perinatal growth-hormone physiology study, not a treatment trial.
GHRH 1-29 postmenopausal women randomized0 recordsNothing at all — no randomized trial of this molecule in postmenopausal women is indexed, which is the population it is most often marketed to.
PubMed, run 2026-07-31. Paste any query above to check it yourself — these are the searches behind the claim that no evidence in women exists, and a claim like that is worth nothing if you cannot repeat it.
Sources: Khorram O 1997; Mendias CL 2026
- Uncontrolled only
BPC-157
The best-selling repair peptide in this market, and the one with the loudest claims.
One all-female human report exists — twelve women with interstitial cystitis, single-arm, unblinded, no control, a one-item subjective outcome, and ten of twelve reporting complete symptom resolution after a single injection. In an unblinded pilot that effect size reads as expectancy, not efficacy. It is nonetheless the only human BPC-157 study in women that exists.
3 searches run · 2 returned nothing
"BPC 157"[tiab] AND randomized controlled trial[pt]0 recordsNo randomized controlled trial of BPC-157 exists in the indexed literature.
"BPC 157"[tiab] AND clinical trial[pt]0 recordsNo indexed clinical trial of any design.
"BPC 157"[tiab] AND (women OR female OR sex)[tiab]4 recordsFour records; two are rat studies.
PubMed, run 2026-07-31. Paste any query above to check it yourself — these are the searches behind the claim that no evidence in women exists, and a claim like that is worth nothing if you cannot repeat it.
Sources: Lee E 2024; Mendias CL 2026
- No human data
TB-500
A fragment of thymosin β4, sold beside BPC-157 as the other half of a repair stack.
No human trial of TB-500 exists in either sex. The only randomized human data is for full-length synthetic thymosin β4 — a different molecule — in a phase 1 safety study of forty healthy volunteers, with no results reported by sex.
3 searches run · 1 returned nothing
"TB-500"[tiab]16 recordsSixteen records, none a human trial of TB-500 itself.
thymosin beta 4 TB-500 human trial0 recordsNothing. TB-500 is a fragment of thymosin beta 4, and the fragment itself has never been given to a person in an indexed trial.
"thymosin beta 4"[tiab] AND randomized controlled trial[pt]3 recordsThree trials, all of the full-length molecule, none reporting by sex.
PubMed, run 2026-07-31. Paste any query above to check it yourself — these are the searches behind the claim that no evidence in women exists, and a claim like that is worth nothing if you cannot repeat it.
Sources: Ruff D 2010; Mendias CL 2026
PCOS: what the trials support, and where the guideline stops
This is the one indication on the page where the trials were run in women by design, so precision is possible. Randomised evidence supports weight and waist reduction, a lower free androgen index, higher SHBG, substantially reduced liver fat and visceral fat, and a modest improvement in bleeding regularity — one 26-week randomised trial put the between-group improvement in bleeding ratio at 0.14 (95% CI 0.03 to 0.24). Note what those endpoints are: almost all of them are surrogates.
The 2023 international evidence-based guideline conditionally supports anti-obesity medications including semaglutide and liraglutide for managing higher weight in PCOS, alongside lifestyle intervention. It then draws a line most summaries omit: use in PCOS for reproductive outcomes only in research settings. No trial has reported live birth. A pooled analysis found a higher natural pregnancy rate — risk ratio 1.72, 95% CI 1.22 to 2.43 — and, in the same analysis, no significant difference in total or IVF pregnancy rate, with the menstrual-regularity estimate carrying heterogeneity of 95.6%, which makes it close to uninterpretable. The guideline's own systematic review calls the published data very limited and could pool only two comparisons across eleven trials.
The practice point that belongs beside all of that: ensure effective contraception where pregnancy is possible, because pregnancy safety data are lacking. Restoring ovulation is one of the ways these drugs work in PCOS — which makes the contraception question above more pressing here, not less.
Perimenopause: the scale is measuring the wrong thing
In the Study of Women's Health Across the Nation, anchored to the final menstrual period rather than to age, the rate of fat gain roughly doubled at the start of the transition and lean mass declined, both continuing until about two years afterwards — while weight climbed linearly throughout with no acceleration at the transition at all. It is a recomposition, not extra pounds, which is why so many women describe a body that changed while the number did not.
Regional measurement in the same cohort found android fat accelerating from 1.21% to 5.54% a year and visceral fat beginning to climb at 6.24% a year — and waist circumference growing at rates that were statistically indistinguishable before, during and after. A tape measure misses this. A related analysis links that lean-mass loss to later bone density and fracture, which moves it out of the cosmetic column entirely.
★ No peptide on this page has been tested against any of that. The interventions with evidence for lean mass and bone are resistance training and adequate protein, and — as a clinical decision with a clinician — hormone therapy. We would rather write that sentence than sell you a compound for it.
What the providers we cover can and cannot do about this
Being straight about the gap, because a page that ranks and cannot deliver is worse than no page. The compounded telehealth providers we review can serve the GLP-1 half well — that is a crowded, competitive market and our board ranks them on whether you can choose your molecule. Exactly one of them runs a women's hormone practice alongside it. None of them offers a PCOS-specific pathway, and none offers the resistance-training and bone-density side of the perimenopause answer, because none of them is that kind of business.
For everything else on this page the honest routing is nowhere. We are not going to point you at a BPC-157 seller on the strength of a twelve-person uncontrolled pilot, and we do not rank one.
Questions we get asked
What are the best peptides for women?
Judged on whether anything has been tested in women, the honest list is short. Of the 5 compound groups on this page, 4 have any human evidence in women at all, and only the GLP-1s — semaglutide and tirzepatide — have randomised evidence on outcomes a person would notice. BPC-157 has one uncontrolled twelve-person report. TB-500 has no human trial in either sex. Sermorelin has no randomised trial indexed under its own name. That is not an argument that the others do not work; it is an accurate statement that nobody has checked.
Do peptides affect birth control?
One of them does, and it is on the label. Tirzepatide delays gastric emptying, and Zepbound's sections 7.2 and 8.3 advise anyone using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. Mounjaro says the same. Semaglutide carries no such advice, and that is backed by measurement rather than by silence — dedicated studies found no reduction in the bioavailability of ethinyl estradiol and levonorgestrel with semaglutide, and Wegovy's own section 12.3 lists both among drugs with no clinically significant difference. Non-oral contraception is unaffected either way. No other compound on this page has been studied for this at all.
Are peptides safe during pregnancy or breastfeeding?
For weight loss the answer is no, and it is stated plainly. Both GLP-1 labels say weight loss offers no benefit to a pregnant patient and may cause fetal harm, and both instruct discontinuation once a pregnancy is recognised. Semaglutide adds a pre-conception interval: discontinue at least 2 months before a planned pregnancy, because of its long half-life. Breastfeeding is now split by formulation — Wegovy tablets carry an affirmative instruction that breastfeeding is not recommended, while the injection gets only standard balancing language. For everything else on this page there is no label, no pregnancy category and no safety data, which is a reason for more caution rather than less.
Do peptides help with PCOS?
GLP-1 receptor agonists have real randomised evidence in PCOS — weight and waist reduction, a lower free androgen index, higher SHBG, less liver and visceral fat, and a modest improvement in bleeding regularity. Two meta-analyses disagree on whether insulin resistance improves. No trial has reported live birth, and the 2023 international evidence-based guideline recommends anti-obesity agents in PCOS for reproductive outcomes only in research settings. No other peptide on this page has been studied in PCOS at all.
Do peptides help with menopause weight gain?
The premise needs correcting before the question can be answered. In the Study of Women's Health Across the Nation, the rate of weight gain did not accelerate at the menopause transition — what changed was the composition: fat gain roughly doubled and lean mass declined, continuing until about two years after the final period. Visceral fat began climbing at 6.24% a year while waist circumference grew at statistically indistinguishable rates throughout, so a tape measure misses it. The intervention with evidence for that specific problem is resistance training plus adequate protein, and, where appropriate, hormone therapy — not a peptide. No peptide on this page has been tested against menopausal body composition.
Sources
Every label was read on DailyMed and every paper pulled from PubMed on 2026-07-31. Identifiers come from the record itself, never from recall.
- 1.Novo Nordisk WEGOVY (semaglutide) injection and tablet — full prescribing information (revised 6/2026) U.S. Food and Drug Administration / DailyMed, 2026 — §7.2 Oral Medications; §8.1 Pregnancy; §8.2 Lactation; §8.3 Females and Males of Reproductive Potential; §6.1 Adverse Reactions; §12.3; §14.2
- 2.Eli Lilly and Company ZEPBOUND (tirzepatide) injection — full prescribing information (revised 4/2026) U.S. Food and Drug Administration / DailyMed, 2026 — §7.2 Drug Interactions; §8.3 Contraception; §12.2; §12.3; §6.1 Adverse Reactions; §14.1
- 3.Novo Nordisk OZEMPIC (semaglutide) injection — full prescribing information (revised 5/2026) U.S. Food and Drug Administration / DailyMed, 2026 — §8.3 Females and Males of Reproductive Potential; §12.3 Drug Interaction Studies
- 4.Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 2023 · PMID 37580037 · doi:10.1093/humrep/dead156
- 5.Goldberg A, Graca S, Liu J, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews, 2024 · PMID 38355887 · doi:10.1111/obr.13704
- 6.Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive BioMedicine Online, 2017 · PMID 28479118 · doi:10.1016/j.rbmo.2017.03.023
- 7.Zhou L, Qu H, Yang L, Shou L Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders, 2023 · PMID 37940910 · doi:10.1186/s12902-023-01500-5
- 8.Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight, 2019 · PMID 30843880 · doi:10.1172/jci.insight.124865
- 9.Greendale GA, Han W, Finkelstein JS, et al. Changes in Regional Fat Distribution and Anthropometric Measures Across the Menopause Transition. The Journal of Clinical Endocrinology and Metabolism, 2021 · PMID 34061966 · doi:10.1210/clinem/dgab389
- 10.Shieh A, Greendale GA, Cauley JA, et al. Menopause-Related Changes in Body Composition Are Associated With Subsequent Bone Mineral Density and Fractures: Study of Women's Health Across the Nation. Journal of Bone and Mineral Research, 2023 · PMID 36542065 · doi:10.1002/jbmr.4759
- 11.Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. The Journal of Clinical Pharmacology, 2015 · PMID 25475122 · doi:10.1002/jcph.443
- 12.Skelley JW, Swearengin K, York AL, Glover LH The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 2024 · PMID 37940101 · doi:10.1016/j.japh.2023.10.037
- 13.Yang Y, Zhao C, Liang J, et al. Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. Journal of Diabetes, 2025 · PMID 40040445 · doi:10.1111/1753-0407.70063
- 14.Alexander GC, Wang T, Ballreich J, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis. JAMA Internal Medicine, 2026 · PMID 41770554 · doi:10.1001/jamainternmed.2025.8222
- 15.Lee E, Padgett B Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine, 2024 · PMID 39325560
- 16.Khorram O, Yeung M, Vu L, Yen SS Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. The Journal of Clinical Endocrinology and Metabolism, 1997 · PMID 9360512 · doi:10.1210/jcem.82.11.4363
- 17.Ruff D, Crockford D, Girardi G, Zhang Y A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences, 2010 · PMID 20536472 · doi:10.1111/j.1749-6632.2010.05474.x
- 18.Mendias CL, Rodeo SA, Hannafin JA, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 2026 · PMID 41966639 · doi:10.1007/s40279-026-02437-0
- 19.Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility, 2022 · PMID 35710599 · doi:10.1016/j.fertnstert.2022.04.027
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.